(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/184858 A8

(51) International Patent Classification:
C07K 16/22 (2006.01) *A61P 35/00* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/CN2024/080506

(22) International Filing Date:
07 March 2024 (07.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicants: **BIOTHEUS INC.** [CN/CN]; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **BIONTECH SE** [DE/DE]; An Der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: **HU, Guoqiang**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **LIU, Jing**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **ZHANG, Juan**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **OU, Yankui**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **DONG, Jie**; 10B, Building 4, No.1, Keji 7th Road, Tangjiawan Town, Zhuhai, Guangdong 519080 (CN). **SAHIN, Ugur**; An Der Goldgrube 12, 55131 Mainz (DE).

(74) Agent: **TEE & HOWE INTELLECTUAL PROPERTY ATTORNEYS**; Suite 1, 6-12, 5th Floor, Tower W1, The Tower Offices, Oriental Plaza, No. 1 East Chang'an Avenue, Dongcheng District, Beijing 100738 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
02 October 2025 (02.10.2025)

(15) Information about Correction:
see Notice of 02 October 2025 (02.10.2025)

WO 2025/184858 A8

(54) Title: COMBINATION THERAPY COMPRISING A BISPECIFIC ANTI-VEGF-A AND ANTI-PD-L1 ANTIBODY AND A CHEMOTHERAPY FOR CANCER TREATMENT

(57) Abstract: The invention relates to a bispecific antibody that specifically binds to programmed death-ligand 1 (PD-L1) and Vascular Endothelial Growth Factor (VEGF) for use in the treatment of a subject afflicted with cancer, wherein the subject is administered a combination comprising the bispecific antibody and a chemotherapy, wherein the subject has a PD-L1 expression score before the treatment as determined by a combined positive score (CPS) of ≥ 1 or other integrating scoring algorithm defining a similar PD-L1 expression score.